SkylineDx Expands Direct U.S. Commercial and Clinical Investment to Accelerate Access to Merlin™ CP-GEP

SkylineDx completed its transition from third-party commercialization to a fully integrated U.S. commercial model. The company has established a dedicated sales, marketing and clinical organization of more than 25 professionals across key U.S. markets, expanding its direct commercialization capabilities. The announcement is operationally positive but provides no revenue, guidance, or profitability metrics.